Pyrimethamine was launched in 1953 for the treatment of malaria as a dihydrofolate reductase (DHFR) inhibitor (www.drugbank.com), and more recently for the treatment of toxoplasmosis combined with a sulfonamide [13,14]. This evidence concerns the gene DHFR and toxoplasmosis.